ETF 日报 2025.06.03 市场概况： 今日 A 股上证综指上涨 0.43%，收于 3361.98 点，深证成指上涨 0.16%，收于 10057.17 点，创业板指上涨 0.48%，收于 2002.70 点， 两市 A 股成交金额为 11640 亿元。涨幅靠前的行业有：美容护理 （3.86%）、纺织服饰（2.53%）、综合（2.02%），跌幅靠前的行业有： 家用电器（-2.10%）、钢铁（-1.37%）、煤炭（-0.84%）。 股票 ETF： 今日成交金额靠前的股票 ETF 为：华夏中证 A500ETF 下跌 0.11%， 贴水率为 0.05%；嘉实中证 A500ETF 下跌 0.31%，贴水率为 0.15%； 华泰柏瑞沪深 300ETF 下跌 0.05%，贴水率为 0.31%。 债券 ETF： 今日成交金额靠前的债券 ETF 为：南方上证基准做市公司债 ETF 下跌 0.02%，贴水率为 0.05%；富国中债 7-10 年政策性金融债 ETF 上涨 0.01%，贴水率为-0.05%；海富通中证短融 ETF 上涨 0.01%， 贴水率为 0.02%。 2025 年 06 月 03 日 ETF 日报 ...

Core Viewpoint - The Hong Kong innovative pharmaceutical sector has gained significant traction in the capital market this year, with a notable performance of related ETFs, indicating strong investor interest and potential growth in the industry [3][5]. Group 1: Performance of ETFs - As of May 30, 2023, the top 17 cross-border ETFs in terms of returns are all related to Hong Kong pharmaceuticals, with annual returns exceeding 40% [3][5]. - Specific ETFs such as the Huatai-PB Hang Seng Innovative Drug ETF and the GF CSI Hong Kong Innovative Drug ETF have reported returns of 43.36% and 42.09% respectively [5]. - The total net inflow of funds into these ETFs has been substantial, with the Huatai-PB ETF seeing an increase of 19.78 million shares [5]. Group 2: Private Equity Interest - Private equity firms have shown a strong preference for newly listed ETFs, particularly in the sci-tech sector, with 104 private equity products appearing in the top ten holdings of 97 newly listed ETFs, holding a total of 1.783 billion shares [3][8]. - The sci-tech ETFs have attracted 32.02% of the total shares held by private equity, indicating a robust interest in high-growth potential sectors [8]. Group 3: Future Outlook for Innovative Pharmaceuticals - Industry experts express optimism regarding the investment potential in innovative pharmaceuticals, citing favorable policies and market conditions as catalysts for growth [4][6]. - The ongoing development of innovative drugs is supported by government initiatives, which aim to streamline approval processes and enhance market access [7][8]. - The increasing demand for innovative drugs is driven by an aging population and heightened health awareness, suggesting a sustainable growth trajectory for the sector [7][8]. Group 4: Free Cash Flow ETFs - Newly listed free cash flow ETFs have emerged as a popular choice among private equity investors, with 16 such ETFs collectively holding 350 million shares [10][12]. - These ETFs focus on companies with strong cash flow, reflecting their true profitability and financial health, which is increasingly appealing in the current market environment [11][12]. - The demand for stable, high-quality investment options has led to a growing interest in free cash flow ETFs, which offer both cash returns and growth potential [12].

Core Viewpoint - COMEX gold prices are currently experiencing a pullback, fluctuating around $3,280 per ounce, while domestic stock and bond markets show low volatility, indicating a potential opportunity for gold investment due to its higher volatility compared to other assets [1]. Group 1: Market Analysis - The Shanghai Gold ETF (518600) has seen active trading, with daily transaction volumes exceeding 100 million yuan, and significant net inflows over the past three months, with shares increasing by 28.8 million, 4.5 million, and 1.314 million respectively [1]. - The 10-year government bond yield has maintained a daily fluctuation within 2 basis points, reflecting a stable macroeconomic environment [1]. Group 2: Investment Strategy - Short-term trading strategy suggests buying gold below $3,150 per ounce and reducing positions above $3,350 per ounce to capitalize on market fluctuations [1]. - Long-term investment outlook remains positive, anticipating a further upward trend in gold prices following the current period of adjustment [1]. Group 3: Product Features - The Shanghai Gold ETF and its associated funds (A class 008986, C class 008987, F class 021738) offer a convenient way to invest in gold without physical delivery, with T+0 trading flexibility and low fees [2][4]. - The ETF has no custody costs and a low minimum investment requirement compared to physical gold, enhancing liquidity with redemption funds available as quickly as T+1 [4].

Group 1 - The first batch of innovative floating rate funds will start selling on May 27, with most products expected to close fundraising between June 17 and June 30, while one fund plans to close on August 26 [1] - Several funds have set fundraising targets, with Guangfa Value Steady Growth aiming for 8 billion yuan and Dongfanghong Core Value targeting 2 billion yuan, while others are mainly focused on 3 billion to 5 billion yuan [1] Group 2 - In the A-share market, 282 pharmaceutical theme funds have shown positive performance, with 66 funds achieving over 20% growth this year, and 155 funds exceeding 10% [2] - There is significant performance divergence among medical theme funds, with the top and bottom funds differing by over 60 percentage points, primarily due to different holdings [2] Group 3 - Hong Kong-themed funds have recently topped performance charts, with the Huatai-PineBridge Hong Kong Advantage Selected Fund leading the market, and over 1,100 funds holding more than 20% of their net asset value in Hong Kong stocks showing positive returns [3] - The number of Hong Kong-themed funds with over 30% growth this year has reached 61, while only 110 funds across the entire market have achieved similar performance [3] Group 4 - QDII funds have shown clear performance divergence this year, with an average net value increase of 9% as of May 21, and the top fund, Huatai-PineBridge Hong Kong Advantage Mixed A, achieving a 66.44% increase [4] - Funds benefiting from the rise of Hong Kong innovative pharmaceuticals and European markets are performing well, while oil-related QDII funds have generally shown negative returns this year [4] Group 5 - As of May 23, the total scale of existing ESG public funds in the domestic market has reached 824.232 billion yuan, with 669 funds in total [5] - The issuance of ESG funds is believed to significantly promote the development of green finance, creating deep linkages in concepts, capital guidance, and market improvement [5] Group 6 - The Hong Kong stock market has become one of the best-performing technology and consumer markets globally this year, attracting many fund managers to showcase growth investment strategies [6] - The market is expected to see significant investment opportunities, with a macro trend of "recovery" anticipated, particularly in technology sectors catalyzed by AI [6]

Group 1 - The recent adjustment in AI-related theme funds contrasts with the strong performance of certain Hong Kong stock funds, with the Huatai-PineBridge Hong Kong Advantage Selected Fund leading the public fund performance this year [1] - Several Hong Kong theme funds and equity funds with heavy Hong Kong stock holdings have achieved returns exceeding 30% year-to-date, indicating a potential shift in investment focus towards Hong Kong stocks [1] - As of May 26, the Hang Seng Index has risen by 16.06% this year, outperforming several major A-share indices, which have seen declines during the same period [1] Group 2 - Analysts suggest that current valuations of Hong Kong stocks are at a historical medium level, and recommend investors focus on sectors such as technology, durable consumer goods, and defense industries [2] - The report highlights the potential benefits for sectors impacted by new regulations on major asset restructurings, particularly for central state-owned enterprises and technology companies [2]

R&D Strategy and Product Pipeline - The company has initiated a comprehensive review of its R&D strategy starting in 2024, focusing on clear and defined strategic lines around disease areas and technology platforms [2][3]. - In the gastrointestinal field, the company is expanding its product lineup with P-CAB tablets and injectables, with P-CAB tablets currently in Phase III clinical trials [3]. - The reproductive health sector has a complete product cycle from ovulation induction to luteal support, with a key product, recombinant human follicle-stimulating hormone injection, reported in January 2023 and expected to enhance the product pipeline [3]. - In the field of mental health, the company is advancing its pipeline with innovative products like NS-041 tablets, which have completed Phase I trials and are moving into Phase II [4]. Key Product Developments - NS-041 tablets are positioned as a best-in-class product for epilepsy, showing superior selectivity and efficacy compared to similar products in development, with a patent protection until 2042 [4]. - The small nucleic acid project LZHN2408 has completed IND filing and targets gout with high patient demand, expected to receive clinical approval soon [5]. - The IL-17A/F monoclonal antibody for psoriasis has completed Phase III clinical enrollment and is expected to launch in 2025, with promising clinical data showing a 60% complete skin clearance rate at 12 weeks [6][7]. Business Development and Market Strategy - The company employs a dual strategy of self-research and business development (BD) to enhance its pipeline, focusing on projects that align with its core areas and technology platforms [9]. - The acquisition of Vietnam's IMP company aims to strengthen innovation and global market presence, leveraging IMP's established marketing network and production capabilities [12]. - The company anticipates steady growth in its traditional Chinese medicine sector, driven by products like the ginseng and astragalus injection, benefiting from policy changes [10][11]. Organizational Changes and Efficiency - The company has enhanced its operational efficiency through systematic improvements in R&D project management, optimizing processes and resource allocation [13]. - Structural adjustments have been made to ensure a stable workforce while optimizing roles, particularly in sales, to support product launches and market penetration [13].

Quantitative Models and Construction Methods 1. Model Name: Shenzhen Benchmark Market-Making Credit Bond Index - **Model Construction Idea**: The index is constructed based on the most liquid and highest-rated corporate bonds listed on the Shenzhen Stock Exchange, aiming to provide a representative and investable benchmark for credit bonds[3][20] - **Model Construction Process**: - **Selection Universe**: Credit bonds listed and traded on the Shenzhen Stock Exchange[20] - **Sample Selection**: Bonds included in the Shenzhen Stock Exchange benchmark market-making bond list, requiring AAA credit rating (either issuer or bond rating) and a minimum outstanding size of 10 billion RMB[20] - **Weighting**: The index adopts a relatively dispersed weighting scheme, with an average weight of 0.47% and a maximum weight of 0.88%, which helps to diversify credit risk[3][23] - **Model Evaluation**: The index demonstrates strong historical performance, with higher returns and lower drawdowns compared to the Wind Medium- to Long-Term Pure Bond Index. It also exhibits lower annualized volatility and maximum drawdown compared to other credit bond indices, making it a low-risk and stable investment tool[3][24][28] 2. Model Name: Dacheng Shenzhen Benchmark Market-Making Credit Bond ETF - **Model Construction Idea**: The ETF aims to closely track the Shenzhen Benchmark Market-Making Credit Bond Index, minimizing tracking deviation and tracking error[5][45] - **Model Construction Process**: - **Investment Strategy**: The ETF primarily adopts a representative stratified sampling replication strategy, investing in representative index constituent bonds or selecting non-constituent bonds as substitutes to ensure the portfolio's overall characteristics (e.g., duration, maturity distribution, and yield to maturity) align with the index[5][45] - **Tracking Objective**: The fund strives to achieve an absolute daily tracking deviation of no more than 0.2% and an annualized tracking error of no more than 2%[5][45] - **Model Evaluation**: The ETF has achieved the highest annualized return (1.9%) and the lowest maximum drawdown (0.75%) among all benchmark market-making credit bond ETFs, demonstrating strong performance and risk control[4][42][44] --- Model Backtesting Results 1. Shenzhen Benchmark Market-Making Credit Bond Index - **2023 Return**: 4.11%[25] - **2024 Return**: 5.24%[25] - **2025 YTD Return**: 0.46%[25] - **2023 Maximum Drawdown**: -0.2%[25] - **2024 Maximum Drawdown**: -0.42%[25] - **2025 YTD Maximum Drawdown**: -0.91%[25] - **Annualized Volatility (2022/6/30-2024/12/31)**: 0.0047[28] - **Maximum Drawdown (2022/6/30-2024/12/31)**: -0.0097[28] - **Calmar Ratio (2022/6/30-2024/12/31)**: 4.32[28] 2. Dacheng Shenzhen Benchmark Market-Making Credit Bond ETF - **Annualized Return**: 1.9%[44] - **Maximum Drawdown**: -0.75%[44] - **Interval Return (2025/2/1-2025/5/19)**: 0.61%[44] - **Interval Excess Return**: 0.10%[44] - **Benchmark Interval Return**: 0.51%[44] - **Benchmark Interval Maximum Drawdown**: -0.91%[44]

Group 1 - The core point of the article highlights the performance and holdings of the Guangfa Healthcare Stock A fund, which has a recent net value of 1.7952 yuan, reflecting a decline of 1.28% [1] - The fund's performance over the past month shows a return of 1.70%, ranking 419 out of 940 in its category; over the past six months, it has achieved a return of 8.97%, ranking 232 out of 914; and since the beginning of the year, it has returned 11.06%, ranking 118 out of 926 [1] - The top ten holdings of the Guangfa Healthcare Stock A fund account for a total of 48.15%, with significant positions in companies such as Zai Lab (10.52%), Kelun Pharmaceutical (8.39%), and others [1] Group 2 - Guangfa Healthcare Stock A fund was established on August 10, 2017, and as of March 31, 2025, it has a total scale of 5.237 billion yuan, managed by fund manager Wu Xingwu [1] - Wu Xingwu has extensive experience in the investment management field, having held various positions in Guangfa Fund Management and previously at Morgan Stanley Huaxin Fund Management [2]

Company Overview - Wangneng Environment Co., Ltd. is headquartered in Huzhou, Zhejiang, the birthplace of the "Two Mountains" concept, and specializes in the comprehensive disposal of solid waste such as municipal waste, kitchen waste, and municipal sludge [1] - The company has ranked among the top ten in the national solid waste industry for eight consecutive years [1] Recent Performance - Wangneng Environment has experienced a decline in stock price, with a cumulative drop of -4.73% over five consecutive trading days as of May 26 [1] - The company has attracted investment from GF Fund's GF Technology Innovation Mixed A fund, which entered the top ten shareholders in the first quarter of this year [1] Fund Manager Profile - The fund manager of GF Technology Innovation Mixed A is Wu Yuanyi, who holds a Master's degree in Science and has extensive experience in investment management [3][4] - Wu has served as a fund manager for multiple funds under GF Fund Management Co., Ltd. since 2020, demonstrating a solid track record in fund management [3][4] Fund Performance - The GF Technology Innovation Mixed A fund has achieved a return of 13.16% year-to-date, ranking 513 out of 4574 in its category [1]

Core Viewpoint - The public fund industry in China is experiencing a steady reduction in management and custody fees, benefiting investors by lowering their investment costs and enhancing their overall experience [1][4][5]. Group 1: Fee Reductions - Multiple leading public fund institutions, including E Fund, Huaxia Fund, and Penghua Fund, have announced reductions in management and custody fees for various fund products since May [1][2]. - Specific examples include E Fund reducing the management fee for its bond funds from 0.30% to 0.15% and from 0.35% to 0.30%, respectively [2]. - The number of products with management fees at or below 0.15% has reached 1009, indicating a significant trend in fee reductions across the industry [4]. Group 2: Impact on Different Fund Types - In addition to bond funds, several ETFs have also reduced their fees, with Penghua Fund lowering its management fee from 0.6% to 0.45% for its technology ETF [3]. - The management fee for Huaxia's gold industry ETF was reduced from 0.50% to 0.15%, showcasing a broader trend of fee reductions across various fund types [3]. Group 3: Industry Dynamics - The fee reduction trend is supported by regulatory guidance aimed at lowering investor costs and enhancing the quality of public fund offerings [5]. - Industry experts suggest that the fee reductions will lead to increased competition among fund managers, particularly affecting smaller firms that may struggle to maintain profitability [5][6]. - The emphasis on research and investment capabilities is seen as crucial for public fund institutions to thrive in a competitive environment, with a focus on delivering strong long-term performance to investors [6].